Literature DB >> 20585096

Bevacizumab-induced diffusion restriction in patients with glioma: tumor progression or surrogate marker of hypoxia?

Johannes Rieger, Oliver Bähr, Michael W Ronellenfitsch, Joachim Steinbach, Elke Hattingen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20585096     DOI： 10.1200/JCO.2010.29.2029

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  9 in total

Review 1.  [Neurological complications of neurooncological therapy].

Authors:  U Herrlinger; J P Steinbach
Journal:  Nervenarzt       Date:  2010-08       Impact factor: 1.214

2.  Selective killing of tumor neovasculature paradoxically improves chemotherapy delivery to tumors.

Authors:  Freddy E Escorcia; Erik Henke; Michael R McDevitt; Carlos H Villa; Peter Smith-Jones; Ronald G Blasberg; Robert Benezra; David A Scheinberg
Journal:  Cancer Res       Date:  2010-11-02       Impact factor: 12.701

3.  Progressing Bevacizumab-Induced Diffusion Restriction Is Associated with Coagulative Necrosis Surrounded by Viable Tumor and Decreased Overall Survival in Patients with Recurrent Glioblastoma.

Authors:  H S Nguyen; N Milbach; S L Hurrell; E Cochran; J Connelly; J A Bovi; C J Schultz; W M Mueller; S D Rand; K M Schmainda; P S LaViolette
Journal:  AJNR Am J Neuroradiol       Date:  2016-08-04       Impact factor: 3.825

4.  Bevacizumab-induced tumor calcifications as a surrogate marker of outcome in patients with glioblastoma.

Authors:  Oliver Bähr; Elke Hattingen; Johannes Rieger; Joachim P Steinbach
Journal:  Neuro Oncol       Date:  2011-07-31       Impact factor: 12.300

Review 5.  Epidermal growth factor receptor and mammalian target of rapamycin as therapeutic targets in malignant glioma: current clinical status and perspectives.

Authors:  Michael W Ronellenfitsch; Joachim P Steinbach; Wolfgang Wick
Journal:  Target Oncol       Date:  2010-09-19       Impact factor: 4.493

6.  Precise ex vivo histological validation of heightened cellularity and diffusion-restricted necrosis in regions of dark apparent diffusion coefficient in 7 cases of high-grade glioma.

Authors:  Peter S LaViolette; Nikolai J Mickevicius; Elizabeth J Cochran; Scott D Rand; Jennifer Connelly; Joseph A Bovi; Mark G Malkin; Wade M Mueller; Kathleen M Schmainda
Journal:  Neuro Oncol       Date:  2014-07-24       Impact factor: 12.300

7.  A comprehensive analysis of vascular complications in 3,889 glioma patients from the German Glioma Network.

Authors:  C Seidel; B Hentschel; M Simon; O Schnell; O Heese; M Tatagiba; D Krex; T Reithmeier; A Kowoll; M Weller; W Wick
Journal:  J Neurol       Date:  2012-10-27       Impact factor: 4.849

8.  Perioperative cerebral ischemia promote infiltrative recurrence in glioblastoma.

Authors:  Anna-Luisa Thiepold; Sebastian Luger; Marlies Wagner; Natalie Filmann; Michael W Ronellenfitsch; Patrick N Harter; Anne K Braczynski; Stephan Dützmann; Elke Hattingen; Joachim P Steinbach; Christian Senft; Johannes Rieger; Oliver Bähr
Journal:  Oncotarget       Date:  2015-06-10

9.  Regorafenib CSF Penetration, Efficacy, and MRI Patterns in Recurrent Malignant Glioma Patients.

Authors:  Pia S Zeiner; Martina Kinzig; Iris Divé; Gabriele D Maurer; Katharina Filipski; Patrick N Harter; Christian Senft; Oliver Bähr; Elke Hattingen; Joachim P Steinbach; Fritz Sörgel; Martin Voss; Eike Steidl; Michael W Ronellenfitsch
Journal:  J Clin Med       Date:  2019-11-21       Impact factor: 4.241
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.